Quinolone compounds for the treatment of disorders caused by
helicobacter pylori
    2.
    发明授权
    Quinolone compounds for the treatment of disorders caused by helicobacter pylori 失效
    喹诺酮化合物用于治疗由幽门螺杆菌引起的疾病

    公开(公告)号:US5942619A

    公开(公告)日:1999-08-24

    申请号:US43374

    申请日:1998-04-24

    摘要: This invention provides processes for producing quinolone compounds which comprise cultivating Amycoa sp. FERM BP-4785, and then isolating quinolone compounds from the fermentation broth. The compounds produced by these processes include compounds of formula (I) wherein R.sup.1 is H, R.sup.2 is (a) and R.sup.3 is CH.sub.3 ; R.sup.1 is CH.sub.3, R.sup.2 is (a) and R.sup.3 is CH.sub.3 ; or R.sup.1 is CH.sub.3, R.sup.2 is (b) and R.sup.3 is CH.sub.3 ; and the like. The present invention also relates to a pharmaceutical composition comprising the same, which is useful in the treatment of diseases, disorders and adverse conditions caused by Helicobacter pylori and is particularly useful in the treatment of gastroduodenal disorders, diseases and adverse conditions caused thereby. ##STR1##

    摘要翻译: PCT No.PCT / IB96 / 00670 Sec。 371日期:1998年4月24日 102(e)1998年4月24日PCT PCT 1996年7月11日PCT公布。 出版物WO97 / 12868 日期:1997年04月10日本发明提供了生产喹诺酮化合物的方法,其中包括培养Amycoa sp。 FERM BP-4785,然后从发酵液中分离出喹诺酮化合物。 通过这些方法制备的化合物包括其中R 1是H,R 2是(a)和R 3是CH 3的式(I)化合物; R1是CH3,R2是(a),R3是CH3; 或R 1为CH 3,R 2为(b),R 3为CH 3; 等等。 本发明还涉及含有该组合物的药物组合物,其可用于治疗由幽门螺杆菌引起的疾病,病症和不利条件,并且特别可用于治疗胃十二指肠疾病,疾病和由此引起的不利条件。